CTIS2023-507790-18-00进行中（未招募）1 期
Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study - 22-377
niversitaetsklinikum Aachen AöR0 个研究点目标入组 24 人开始时间: 2024年6月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subject has cirrhosis of any etiology based on clinical standard criteria, imaging findings, and/or histology., Subject is diagnosed with ascites and has undergone paracentesis or diagnostic ascitic tap within the last 30 days prior to study inclusion., Subject age is between 18 and 70 years at the time of study inclusion., Subject is able to swallow the Investigational Medicinal Product (IMP) Fecal Microbiota Transfer capsules or placebo., Subject is mentally and physically able to understand the significance and scope of the study and to comply with the study protocol., A written informed consent form has been signed prior to participation in the study.
排除标准
- •Subject has acute-on-chronic liver failure (ACLF) grade 2 or higher according to the EASL-CLIF Consortium definition., Subject is not willing to take adequately safe contraceptive measures., Study participation is, at the discretion of the investigator, an unacceptable risk due to pre-existing or concomitant disease or due to the patient's general underlying condition., There is a current or past medically relevant disease or treatment that could influence the evaluation of the study., Subject has received an investigational drug in another study within the last 30 days before study inclusion., Concurrent participation in another clinical intervention study., Subject is institutionalized due to an official or court order., Subject is in a dependent relationship or employment relationship with the sponsor or investigator., Subject has Model for End-Stage Liver Disease (MELD) score >20., Subject has received systemic antibiotics within 7 days prior to study inclusion, except for stable doses of norfloxacin or rifaximin., Subject has active malignancy or history of malignancy, which was not curatively treated (excluding non-melanoma skin cancer)., Subject receives treatment with immunomodulatory drugs, including corticosteroids, thiopurines, calcineurin inhibitors, and mycophenolate currently or within 90 days prior to study inclusion., Subject has a history of hypersensitivity or allergies to the investigational capsule coating substances or to any compound of INTESTIFIX 001 or placebo., Subject has an expected lack of compliance., Subject has a life expectancy of less than six months., Subject is pregnant or breastfeeding.
研究者
相似试验
招募中
2 期
Encapsulated Faecal Microbiota Transplantation to Preserve Residual Beta Cell Function in Patients with Recently-Diagnosed Type 1 Diabetes MellitusJuveline diabetes10012653type 1 diabetes mellitusNL-OMON50429niversitair Medisch Centrum10
撤回
2 期
Fecal Microbiota Transplantation for eradication of Vancomycin-resistant Enterococci (FAVOR): a pilot studyCarriage of vancomycin-resistant Enterococvancomycin-resistant Enterococ carrier10004018NL-OMON46675niversitair Medisch Centrum Utrecht10
招募中
2 期
Fecal microbiota transplantation for intractable gastrointestinal diseases(FEMIGI study)1)Clostridium difficile infection 2)Crohn disease, ulcerative colitis 3)Chronic Enteropathy associatJPRN-jRCTs041190021Ohmiya Naoki50
尚未招募
不适用
Fecal microbiota transplantation for eradication of Vancomycin-Resistant EnterococciVancomycin-resistant Enterococci carriageAntibiotic resistanceDragerschap vancomycine-resistente Enterococ Antibiotica resistentieNL-OMON25381niversity Medical Center Utrecht10
进行中（未招募）
Unknown
Role of transplantation of fecal microbiota from healthy individuals to patients with Crohn's disease and its effect on achieving control of disease activityCrohn's disease of both small and large intestineDigestive SystemISRCTN15318304Dayanand Medical College & Hospital36